查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1875958

基于次世代定序技术的RNA定序全球市场

NGS-Based RNA-Sequencing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球基于次世代定序(NGS) 的 RNA定序市场规模将达到 97 亿美元。

全球基于次世代定序（NGS）的RNA定序市场规模预计在2024年为32亿美元，到2030年将达到97亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为20.1%。本报告分析的细分市场之一「定序平台及耗材」预计将以20.7%的复合年增长率成长，并在分析期间结束时达到51亿美元。同时，「样本製备」细分市场预计在分析期间内将以17.4%的复合年增长率成长。

美国市场规模估计为8.736亿美元，而中国市场预计将以18.6%的复合年增长率成长。

预计到2024年，美国基于次世代定序（NGS）技术的RNA定序市场规模将达到8.736亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到14亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）将达到18.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期内，它们的复合年增长率将分别达到18.3%和17.1%。在欧洲，德国预计将以约14.3%的复合年增长率成长。

全球基于NGS的RNA定序市场—主要市场趋势与驱动因素概述

什么是基于次世代定序（NGS）的RNA定序？为什么它正在彻底改变基因组学领域？

基于次世代定序（NGS）的RNA定序（RNA-Seq）是一种高通量技术，它使科学家能够以前所未有的分辨率分析整个转录组，并识别和定量样本中的RNA分子。此方法使研究人员能够探索基因表现、检测新的转录物并揭示可变剪接事件，这对于理解细胞功能至关重要。与传统定序技术不同，基于NGS的RNA-Seq能够提供更全面的转录组视图，帮助肿瘤学、神经病学和免疫学等领域的研究人员更好地了解疾病并开发新的治疗方法。

基于次世代定序技术的RNA定序意义重大，其能够捕捉不同组织、发育阶段和疾病状态下基因表现的动态变化。透过揭示不同环境下基因调控与表现的机制，RNA定序在生物标记发现、药物研发和精准医疗领域具有极高的应用价值。 RNA定序能够研究环境因素、基因突变和治疗性介入对基因活性的影响，使其成为基础研究和临床应用领域的创新工具。

基于次世代定序（NGS）的RNA定序市场正在如何发展？

由于技术进步和定序成本的下降，基于次世代定序（NGS）的RNA定序市场正在快速发展。其中一个关键趋势是单细胞RNA定序（scRNA-Seq）的发展，它使研究人员能够在单细胞层级分析基因表现。这项技术能够更详细地展现细胞异质性，从而发现组织内的稀有细胞类型、细胞状态转变以及免疫反应。 scRNA-Seq的整合应用在癌症研究等领域变得至关重要，因为了解肿瘤微环境和免疫细胞相互作用有助于开发更具靶向性的治疗方法。

另一个重要趋势是RNA定序在临床诊断中的应用日益广泛，尤其是在癌症和罕见遗传疾病领域。随着精准医疗的蓬勃发展，RNA定序正被用于识别疾病特异性的基因表现，从而指导治疗决策。此外，云端基础平台的RNA定序资料分析应用也日益普及，使研究人员能够更有效率地处理和解读大型资料集。这些进步使得RNA定序能够惠及更广泛的研究人员和临床医生，进一步推动了其在学术界和商业领域的应用。

哪些产业正在主导基于NGS的RNA定序的应用？

基于新一代定序技术的RNA定序已在学术研究和製药产业中广泛使用。在生物医学研究领域，大学和研究机构利用RNA定序技术研究多种疾病（包括癌症、心血管疾病和神经系统疾病）的基因表现模式。这项技术对于阐明疾病机制和识别潜在的治疗标靶至关重要。尤其是在癌症研究领域，RNA定序技术的应用正主导癌基因、抑癌基因和抗药性机制的发现。

在製药和生物技术产业，RNA定序也是药物发现和开发中重要的技术。製药公司利用RNA定序来识别可用于新型治疗方法的生物标记物，并监测临床试验中患者的反应。在临床诊断领域，RNA定序正被整合到精准医疗计画中，以根据患者独特的基因和转录组特征开发个人化治疗方案。在农业领域，RNA定序也被用于改良作物和研究植物-病原体相互作用，凸显了其跨产业的广泛应用。

推动次世代定序（NGS）RNA定序市场成长要素是什么？

基于次世代定序（NGS）的RNA定序市场成长受多种因素驱动，其中定序成本的下降是最重要的因素之一。随着基因组定序成本的持续降低，RNA定序技术对研究人员和临床医生变得更加普及，从而在各个领域中广泛应用。另一个主要驱动因素是人们对个人化医疗的日益关注，个人化医疗高度依赖转录组数据来为每位患者制定量身定制的治疗方法。 RNA测序能够提供开发个人化疗法所需的详细基因表现讯息，尤其是在肿瘤学和罕见遗传疾病领域。

单细胞RNA定序等技术进步也推动了市场成长，因为它们能够对基因表现进行更详细、更精确的分析。 RNA测序在临床诊断领域的扩展也是一个关键因素，因为医疗机构越来越多地使用基于RNA的检测方法来诊断疾病和监测治疗效果。此外，人们对了解免疫系统和微生物组等复杂生物系统的兴趣日益浓厚，也推动了对RNA测序的需求，因为RNA测序能够提供关于基因调控和相互作用网络的深入见解。

部分：

按产品/服务（定序平台/耗材、样品製备、定序服务、数据分析、储存/管理）、按技术（合成定定序(SBS)、单分子即时定序 (SMRT)、离子半导体定定序、奈米孔定序）、按应用（研究中心/学术机构、医院/诊所、製药/生物技术公司、其他应用）定序

受访公司范例

  • Agilent Technologies, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • Illumina, Inc.
  • Macrogen, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，革新市场和竞争情报分析。

Market Glass, Inc. 并没有查询LLM 或产业专用的SLM 的典型方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视频转录、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在地、製造地以及进出口（成品和OEM产品）情况，预测企业竞争地位的变化。这种复杂多变的市场现实会从多个方面影响竞争对手，包括增加销货成本、降低盈利和重组供应链，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP13599

Global NGS-Based RNA-Sequencing Market to Reach US$9.7 Billion by 2030

The global market for NGS-Based RNA-Sequencing estimated at US$3.2 Billion in the year 2024, is expected to reach US$9.7 Billion by 2030, growing at a CAGR of 20.1% over the analysis period 2024-2030. Sequencing Platforms & Consumables, one of the segments analyzed in the report, is expected to record a 20.7% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Sample Preparation segment is estimated at 17.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$873.6 Million While China is Forecast to Grow at 18.6% CAGR

The NGS-Based RNA-Sequencing market in the U.S. is estimated at US$873.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 18.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.3% and 17.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global NGS-Based RNA-Sequencing Market - Key Trends & Drivers Summarized

What Is NGS-Based RNA-Sequencing and Why Is It Transformative for Genomics?

Next-Generation Sequencing (NGS)-based RNA sequencing (RNA-Seq) is a high-throughput technique that allows scientists to analyze the entire transcriptome, identifying and quantifying RNA molecules in a sample at unprecedented resolution. This method enables researchers to explore gene expression, detect novel transcripts, and uncover alternative splicing events that are critical for understanding cellular functions. Unlike traditional sequencing technologies, NGS-based RNA-Seq provides a more comprehensive view of the transcriptome, helping researchers in fields like oncology, neurology, and immunology advance their understanding of diseases and develop new therapies.

The significance of NGS-based RNA sequencing lies in its ability to capture a dynamic picture of gene expression across various tissues, stages of development, and disease conditions. It is instrumental in biomarker discovery, drug development, and precision medicine by offering insights into how genes are regulated and expressed in different contexts. With RNA-Seq, researchers can investigate how environmental factors, genetic mutations, or therapeutic interventions affect gene activity, making it a transformative tool in both basic research and clinical applications.

How Is the NGS-Based RNA-Sequencing Market Evolving?

The NGS-based RNA sequencing market is evolving rapidly, driven by technological advancements and decreasing costs of sequencing. One of the key trends is the development of single-cell RNA sequencing (scRNA-Seq), which allows researchers to analyze gene expression at the single-cell level. This technique provides a more granular view of cellular heterogeneity, enabling the discovery of rare cell types, cell-state transitions, and immune responses within tissues. The integration of scRNA-Seq is becoming essential in areas like cancer research, where understanding tumor microenvironments and immune cell interactions can lead to better-targeted therapies.

Another significant trend is the increasing application of RNA-Seq in clinical diagnostics, particularly for cancer and rare genetic diseases. As precision medicine initiatives gain momentum, RNA-Seq is being used to identify disease-specific gene expression signatures that can guide treatment decisions. Additionally, the use of cloud-based platforms for RNA-Seq data analysis is growing, allowing researchers to process and interpret large datasets more efficiently. These advancements are making RNA-Seq more accessible to a broader range of researchers and clinicians, further expanding its adoption in both academic and commercial settings.

Which Industries Are Leading the Adoption of NGS-Based RNA-Sequencing?

NGS-based RNA sequencing is being widely adopted in both academic research and the pharmaceutical industry. In biomedical research, universities and research institutions are using RNA-Seq to study gene expression patterns in various diseases, including cancer, cardiovascular diseases, and neurological disorders. This technology is critical for understanding disease mechanisms and identifying potential therapeutic targets. Cancer research, in particular, is leading the adoption of RNA-Seq as it enables the discovery of oncogenes, tumor suppressor genes, and drug resistance mechanisms.

The pharmaceutical and biotechnology industries are also significant adopters of RNA-Seq, leveraging it for drug discovery and development. Pharmaceutical companies use RNA-Seq to identify biomarkers that can be targeted by new therapies, as well as to monitor patient responses to treatments in clinical trials. In clinical diagnostics, RNA-Seq is being integrated into precision medicine programs to develop personalized treatments based on a patient's unique genetic and transcriptomic profile. The agricultural sector is also exploring RNA-Seq for crop improvement and the study of plant-pathogen interactions, highlighting its versatility across industries.

What Are the Key Growth Drivers in the NGS-Based RNA-Sequencing Market?

The growth in the NGS-based RNA sequencing market is driven by several factors, with the decreasing cost of sequencing being one of the most significant. As the cost per genome continues to drop, RNA-Seq is becoming more accessible to researchers and clinicians, leading to wider adoption across various fields. Another key driver is the increasing focus on precision medicine, which relies heavily on transcriptomic data to tailor treatments for individual patients. RNA-Seq provides the detailed gene expression information needed to develop personalized therapies, particularly in oncology and rare genetic disorders.

Technological advancements, such as single-cell RNA sequencing, are also propelling market growth by enabling more detailed and accurate analysis of gene expression. The expansion of RNA-Seq into clinical diagnostics is another important factor, as healthcare providers increasingly use RNA-based tests to diagnose diseases and monitor treatment responses. Additionally, the growing interest in understanding complex biological systems, such as the immune system and microbiome, is fueling demand for RNA-Seq as it offers deep insights into gene regulation and interaction networks.

SCOPE OF STUDY:

The report analyzes the NGS-Based RNA-Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services, Data Analysis, Storage & Management); Technology (Sequencing by Synthesis (SBS), Single-Molecule Real-time (SMRT) Sequencing, Ion Semiconductor Sequencing, Nanopore Sequencing); End-Use (Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Agilent Technologies, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • Illumina, Inc.
  • Macrogen, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • NGS-Based RNA-Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Next-Generation Sequencing (NGS) Technologies Drives Growth in RNA-Sequencing for Precision Medicine
    • Increasing Demand for RNA-Seq in Cancer Research Expands Opportunities for Biomarker Discovery and Targeted Therapies
    • Technological Advancements in Single-Cell RNA-Sequencing Propel Growth in Genomic Research and Cellular Analysis
    • Growing Use of NGS-Based RNA-Sequencing in Drug Development Fuels Market for High-Throughput Genomic Profiling
    • Rising Focus on Transcriptomics Expands Market for NGS-Based RNA-Sequencing in Understanding Gene Expression Patterns
    • Increasing Use of RNA-Sequencing in Neurodegenerative Disease Research Strengthens Demand in Neuroscience
    • Emerging Applications of RNA-Seq in Personalized Medicine Drive Growth in Precision Diagnostics and Therapeutic Development
    • Technological Innovations in NGS Platforms Strengthen Market for RNA-Sequencing in Multi-Omics and Systems Biology Studies
    • Growing Adoption of RNA-Seq in Infectious Disease Research Expands Market for Pathogen Identification and Vaccine Development
    • Rising Interest in RNA-Seq for Studying Non-Coding RNAs Expands Opportunities in Gene Regulation and Epigenetics Research
    • Advancements in Bioinformatics and Data Analysis Tools Propel Growth in RNA-Sequencing for Complex Data Interpretation
    • Increasing Use of RNA-Seq in Agricultural Genomics Expands Market for Crop Improvement and Livestock Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World NGS-Based RNA-Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for NGS-Based RNA-Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Sequencing Platforms & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Sequencing Platforms & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Sample Preparation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Sample Preparation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sequencing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Sequencing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Data Analysis, Storage & Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Data Analysis, Storage & Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Sequencing by Synthesis (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Sequencing by Synthesis (SBS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ion Semiconductor Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Ion Semiconductor Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Single-molecule Real-time (SMRT) Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Single-molecule Real-time (SMRT) Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Nanopore Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research Centers & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Research Centers & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION